Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 165

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Comparison of vildagliptin and acarbose monotherapy in patients with Type 2 diabetes: a 24‐week, double‐blind, randomized trial

Open access
Pan, C., Yang, W., Barona, J. P., Wang, Y., Niggli, M., Mohideen, P., Wang, Y., Foley, J. E. · 2008 · Diabetic Medicine

Abstract

Aims To compare the efficacy and tolerability of the dipeptidyl peptidase‐4 inhibitor, vildagliptin, with the alpha glucosidase inhibitor, acarbose, in drug‐naive patients with Type 2 diabetes. Methods This multi‐centre, randomized, double‐blind, parallel‐arm study compared the efficacy and tolerability of vildagliptin (100 mg daily, given as 50 mg twice daily, n = 441) and acarbose (up to 300 mg daily, given as three equally divided doses, n = 220) during 24‐week treatment in drug‐naive patients with Type 2 diabetes. Results Monotherapy with vildagliptin or acarbose decreased glycated haemoglobin (HbA 1c) (baseline ≈ 8.6%) to a similar extent during 24‐week treatment. The adjusted mean change from baseline to end‐point (AMΔ) in HbA 1c was −1.4 ± 0.1% and −1.3 ± 0.1% in patients receiving vildagliptin and acarbose, respectively, meeting the statistical criterion for non‐inferiority (upper limit of 95% confidence interval for between‐treatment difference ≤ 0.4%). The decrease in fasting plasma glucose was similar with acarbose (−1.5 ± 0.2 mmol/l) and vildagliptin (−1.2 ± 0.1 mmol/l). Body weight did not change in vildagliptin‐treated patients (−0.4 ± 0.1 kg) but decreased in acarbose‐treated patients (−1.7 ± 0.2 kg, P < 0.001 vs. vildagliptin). The proportion of patients experiencing any adverse event (AE) was 35% vs. 51% in patients receiving vildagliptin or acarbose, respectively; gastrointestinal AEs were significantly more frequent with acarbose (25.5%) than vildagliptin (12.3%, P < 0.001). No hypoglycaemia was reported for either group. Conclusions Vildagliptin is effective and well tolerated in patients with Type 2 diabetes, demonstrating similar glycaemic reductions to acarbose, but with better tolerability.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1464-5491.2008.02391.x

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 165

Metadata

Authors
Pan, C., Yang, W., Barona, J. P., Wang, Y., Niggli, M., Mohideen, P., Wang, Y., & Foley, J. E.
Venue
Diabetic Medicine
Publisher
Wiley
Published
2008-03-13
Volume
25
Issue
4
Pages
435-441
ISSN
  • 0742-3071 (ISSN-L)
  • 1464-5491
OpenAlex
W2099677425
Cited by
165
References
5
FWCI
12.85
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Comparison of vildagliptin and acarbose monotherapy in patients with Type 2 diabetes: a 24‐week, double‐blind, randomized trial. https://app.cochat.ai/papers/10.1111/j.1464-5491.2008.02391.x
The paper
Pan, C., Yang, W., Barona, J. P., Wang, Y., Niggli, M., Mohideen, P., Wang, Y., & Foley, J. E. (2008). Comparison of vildagliptin and acarbose monotherapy in patients with Type 2 diabetes: a 24‐week, double‐blind, randomized trial. Diabetic Medicine. https://doi.org/10.1111/j.1464-5491.2008.02391.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.